Incontinence Related to Management of Benign Prostatic Hypertrophy

American Journal Geriatric Pharmacotherapy

Volumn 5, Issue 4, 2007, Pages 324-334

  Han, Euna ^a,c   Black, Libby K ^b   Lavelle, John P ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

logistic regression; matched case control study; risk factors; urinary incontinence

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; DRUG SAFETY; DRUG USE; HUMAN; INCIDENCE; LASER SURGERY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR; SHORT COURSE THERAPY; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; TREATMENT DURATION; URINE INCONTINENCE; UROLOGIC EXAMINATION; WATCHFUL WAITING;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; CASE-CONTROL STUDIES; DATABASES, FACTUAL; ENZYME INHIBITORS; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; RISK FACTORS; URINARY INCONTINENCE;

EID: 37549021425     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2007.12.003     Document Type: Article

References (24)

1. Thom D. Variation in estimates of urinary incontinence prevalence in the community: Effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 46 (1998) 473-480
2. Wilson L., Brown J., Shin G., et al. Annual direct cost of urinary incontinence. Obstet Gynecol 98 (2001) 398-406
3. Stewart W., Van Rooyen J., Cundiff G., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
4. Coyne K., Zhou Z., Thompson C., and Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 92 (2003) 731-735
5. Fultz N., and Herzog AR. Self-reported social and emotional impact of urinary incontinence. J Am Geriatr Soc 49 (2001) 892-899
6. Criner JA. Urinary incontinence in a vulnerable population: Older women. Sernin Perioper Nuts 10 (2001) 33-37
7. Vinker S., Kaplan B., Nakar S., et al. Urinary incontinence in women: Prevalence, characteristics and effect on quality of life. A primary care clinic study. Isr Med Assoc J. 3 (2001) 663-666
8. Ramon J., Leandri P., Rossignol G., and Gautier J. Urinary continence following radical retropubic prostatectomy. Br J Urol 71 (1993) 47-51
9. Steiner M., Morton R., and Walsh P. Impact of anatomical radical prostatectomy on urinary continence. J Urol 145 (1991) 512-515
10. Kaplan S., Ikeguchi E., Santarosa R., et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology 47 (1996) 836-839
11. Rosenberg M., Staskin D., Kaplan S., et al. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 619: (2007) 1535-1546
12. Kaplan S., McConnell J., Roehrborn C., et al., for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 mL or greater. J Urol 175 (2006) 217-221
13. American FactFinder. 2006 American Community Survey: Data profile highlights [US Census Bureau Website], http://www.factfinder.census.gov/servlet/ACSSAFFFacts?_submenuld=factsheetlesse=on. Accessed December 2, 2006.
14. Roehrborn C., and Schwinn D. Alphal-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171 (2004) 1029-1035
15. Cam K., Akman Y., Kayikci, et al. Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms. Int J Urol 10 (2003) 582-586
16. Drake M., Nixon P., and Crew J. Drug-induced bladder and urinary disorders. Incidence, prevention, and management. Drug Saf 19 (1998) 45-55
17. Carruthers S. Adverse effects of alpha 1-adrenergic blocking drugs. Drug Saf 11 (1994) 12-20
18. Kiruluta H., and Andrews K. Urinary incontinence secondary to drugs. Urology 22 (1983) 88-90
19. Yoshiyama M., and De Groat W. Role of spinal alphaladrenoceptor subtypes in the bladder reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 280 (2001) R1414-R1419
20. de la Rosette J., Alivizatos G., Madersbacher S., et al., for the European Association of Urology. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 40 (2001) 256-263 discussion 264
21. Ellerkmann R., and McBride A. Management of obstructive voiding dysfunction. Drugs Today (Barc) 39 (2003) 513-540
22. McConnel J. Epidemiology, etiology, pathophysiology, and diagnosis of benign prostatic hyperplasia. In: Walsh P., Retik A., Vaughan E., and Wein A. (Eds). Campbell's Urology. 7th (1998), WB Saunders Co, Philadelphia, Pa 223-227
23. Diokno A., Estanol M., Ibrahim I., and Balasubramaniam M. Prevalence of urinary incontinence in community dwelling men: A cross sectional nationwide epidemiological survey. Int Urol Nephrol 39 (2007) 129-136
24. Centers for Medicare & Medicaid Services, Pay-for-Performance. Health Care Financing Review. 2007;29(1). http ://www.cms.hhs.gov/HealthCareFinancingReview/08_2007%20Edition.asp#TopOfPage. Accessed November 16, 2007.